EP0918853A2 - Arn antisens avec une structure secondaire - Google Patents

Arn antisens avec une structure secondaire

Info

Publication number
EP0918853A2
EP0918853A2 EP97936610A EP97936610A EP0918853A2 EP 0918853 A2 EP0918853 A2 EP 0918853A2 EP 97936610 A EP97936610 A EP 97936610A EP 97936610 A EP97936610 A EP 97936610A EP 0918853 A2 EP0918853 A2 EP 0918853A2
Authority
EP
European Patent Office
Prior art keywords
sense rna
expression
vector
secondary structure
pj3ω
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97936610A
Other languages
German (de)
English (en)
Inventor
Dieter Werner
Christof Granzow
Gaby Joswig
Karsten Rothbarth
Marie Schubert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of EP0918853A2 publication Critical patent/EP0918853A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01028—Chloramphenicol O-acetyltransferase (2.3.1.28)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Definitions

  • the present invention relates to an anti-sense RNA with a secondary structure, a combination containing it and the use of both.
  • New techniques for inhibiting gene expression often involve the use of anti-sense RNA.
  • This is an RNA that is complementary to and binds to regions of the mRNA of a gene.
  • a duplex molecule is formed that is not translated by the mRNA. An inhibition of gene expression can thus be achieved.
  • duplex molecule is often not stable, i.e. the mRNA becomes free for translation again, whereby the inhibition of gene expression is weak or does not occur at all.
  • the present invention is therefore based on the object of providing a means with which a strong inhibition of gene expression can be achieved.
  • anti-sense RNA encompasses any RNA molecule which is suitable as anti-sense RNA, ie is complementary to regions of an RNA, in particular mRNA and very particularly regulatory elements thereof, and by binding to these regions inhibits the Gene expression.
  • the anti-sense RNA can also include DNA sequences.
  • the anti-sense RNA can be present as such or in the form of a vector encoding it. Such a vector can be a common expression vector. It can be favorable if the expression of the sequence coding for the anti-sense RNA is under the control of a constitutive or inducible promoter, such as a tissue- or tumor-specific promoter.
  • secondary structure encompasses any DNA and / or RNA sequence which can be present in an anti-sense RNA and which has an at least partially “hairpin” structure, ie individual base pairs are subject to refolding.
  • the secondary structure can exist within the anti-sense RNA. It can also be present at the 5 'and / or 3' end of the anti-sense RNA. If there are several secondary structures, these can be the same or different from one another.
  • Complicated palindromes such as (AGCT) n or (GAATTC) n are also preferred.
  • An anti-sense RNA according to the invention can be produced by customary methods. It is favorable to produce a double-stranded (GC) 20 EcoRI (GC) 20 sequence by oligonucleotide synthesis and to ligate this to the 5 'end of the cDNA sequence of a gene to be inhibited. The DNA molecule obtained is ligated in the 3 ' ⁇ 5' direction to the promoter of a vector. The vector obtained leads to the expression of the anti-sense RNA according to the invention.
  • GC double-stranded
  • EcoRI GC
  • An anti-sense RNA according to the invention can be introduced into cells as such or in the form of a vector encoding it.
  • the cells can be any cells, such as plant and animal, especially mammalian and very particularly human cells.
  • the cells can be inside or outside of an organism. The latter can be freshly isolated or kept in culture.
  • the anti-sense RNA can be introduced into the cells by conventional transfection techniques, such as electroporation.
  • Another object of the present invention is a combination of an anti-sense RNA according to the invention and a (ds) RNAse. This is an RNAse that can recognize and break down double-stranded RNA.
  • a (ds) RNAse is found, for example, in the yeast strain Schizosaccharomyces pombe (pad +).
  • the anti-sense RNA according to the invention can be present as such or in the form of a vector encoding it.
  • the (ds) RNAse can be present as such or in the form of a vector encoding it.
  • a vector can be a common expression vector. It can be advantageous if the expression of the sequence coding for the (ds) RNAse is under the control of a constitutive or inducible promoter, such as a tissue- or tumor-specific one
  • the combination consists in the presence of a vector which codes both for the anti-sense RNA according to the invention and for the (ds) RNAse.
  • vector With regard to the vector, reference is made to the above statements.
  • the combination of an anti-sense RNA according to the invention and a (ds) RNAse can be introduced into cells.
  • the (ds) RNAse as such, i.e. as a protein, by conventional methods such as lipofection.
  • the form of a vector encoding it the
  • RNAse can be introduced by methods as they were called for the anti-sense RNA.
  • the present invention provides an anti-sense RNA and a combination containing it which cause potent inhibition of gene expression.
  • the present invention is thus widely used in molecular biology and medicine.
  • diseases in which individual proteins trigger or reinforce are, for example, diseases in which hormones play a major role, tumor diseases and viral infections, such as HIV and AIDS.
  • diseases in which hormones play a major role are, for example, diseases in which hormones play a major role, tumor diseases and viral infections, such as HIV and AIDS.
  • FIG. 1 shows the inhibition of gene expression by an anti-sense RNA according to the invention.
  • (1) is the rate of expression of the CAT gene in the presence of an anti-sense RNA.
  • (2) is the expression rate of the
  • CAT gene in the presence of an anti-sense RNA with secondary structure I.
  • (3) is the expression rate of the CAT gene in the presence of an anti-sense RNA with secondary structure II.
  • FIG. 2 shows the inhibition of gene expression by an anti-sense RNA according to the invention.
  • (1) is the rate of expression of the CAT gene in the presence of an anti-sense RNA with secondary structure I.
  • (2) is the rate of expression of the CAT gene in the presence of an anti-sense RNA with secondary structure I and a (ds) RNAse.
  • Example 1 Production of expression vectors which contain the chioramphenicolacetyl transferase (CAT) gene in the 5 ' ⁇ 3' or 3 ' ⁇ 5' direction.
  • CAT chioramphenicolacetyl transferase
  • the CAT gene was isolated from a conventional CAT vector and inserted into the "multiple cloning site" of the expression vector pJ3 ⁇ (cf. Nuclear acids res. 1 8, (1 990), 1068). In one case the insertion was in the 5 ' ⁇ 3' direction and the expression vector pJ3 ⁇ -CAT was obtained. In the other case, the insertion was carried out in the 3 '- * 5' direction and the expression vector pJ3 ⁇ -TAC was obtained.
  • Example 2 Production of expression vectors which contain the CAT gene in the 3 ' ⁇ 5' direction and a sequence coding for a secondary structure I or II.
  • AATTC- (GO 20-GAATTC- (GC) 20-GAATTC- (GC) 0-G.
  • Cloning vector pBluescript (Stratagene) was used, from which it could be removed by suitable restriction enzymes for recloning into the vector which has the CAT gene in the 3 '- * 5' direction.
  • the vector pJ3 ⁇ -TAC from Example 1 was cut in the "multiple cloning site" between the promoter and the TAC insert with suitable restriction enzymes.
  • Sequence was taken from the pBluescript vector of Example 2 (e) with the appropriate enzymes. The two nucleic acids were linked by ligation.
  • Example 3 Preparation of an expression vector which codes for a (ds) RNAse.
  • the gene (pad +) coding for a (ds) RNAse was isolated from a conventional genomic library of Schizosaccharomyces pombe by means of PCR amplification. For this purpose, primers were used which had been derived from the known sequence of the pad + gene (cf. database: embl: S78982). The pad + gene was cloned in the known vector pBluescript and confirmed by sequencing. After cloning into the usual expression vector pcDNA3 (InVitrogen), the expression vector pcDNA3-pad + was obtained.
  • Example 4 Inhibition of gene expression by an anti-sense RNA with a secondary structure
  • Ehrlich ascites tumor cells (10 7 cells / ml) were expressed with the expression vectors pJ3 ⁇ -CAT, pJ3 ⁇ -TAC, pJ3 ⁇ -TAC-sec. I or pJ3 ⁇ -TAC-sec. II transfected (see Table 1).
  • RNAse activity is produced or generated by means of the described methods.

Abstract

L'invention concerne un ARN antisens avec des structures secondaires particulières, ainsi qu'une combinaison de cet ARN antisens et d'une (ds)RNase. L'ARN antisens et cette combinaison sont utiles pour inhiber l'expression de gènes.
EP97936610A 1996-08-07 1997-08-05 Arn antisens avec une structure secondaire Withdrawn EP0918853A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1996131919 DE19631919C2 (de) 1996-08-07 1996-08-07 Anti-Sinn-RNA mit Sekundärstruktur
DE19631919 1996-08-07
PCT/DE1997/001691 WO1998005770A2 (fr) 1996-08-07 1997-08-05 Arn antisens avec une structure secondaire

Publications (1)

Publication Number Publication Date
EP0918853A2 true EP0918853A2 (fr) 1999-06-02

Family

ID=7802056

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97936610A Withdrawn EP0918853A2 (fr) 1996-08-07 1997-08-05 Arn antisens avec une structure secondaire

Country Status (3)

Country Link
EP (1) EP0918853A2 (fr)
DE (1) DE19631919C2 (fr)
WO (1) WO1998005770A2 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
KR101085210B1 (ko) 1998-03-20 2011-11-21 커먼웰쓰 사이언티픽 앤드 인더스트리얼 리서치 오가니제이션 유전자 발현 조절방법
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US8598332B1 (en) 1998-04-08 2013-12-03 Bayer Cropscience N.V. Methods and means for obtaining modified phenotypes
JP5015373B2 (ja) * 1998-04-08 2012-08-29 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション 改良表現型を得るための方法及び手段
US20040214330A1 (en) 1999-04-07 2004-10-28 Waterhouse Peter Michael Methods and means for obtaining modified phenotypes
GB9827152D0 (en) * 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
AU2008202208C1 (en) * 1999-01-30 2014-04-24 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a defined gene
WO2000063364A2 (fr) 1999-04-21 2000-10-26 American Home Products Corporation Procedes et compositions pour l'inhibition de la fonction de sequences polynucleotidiques
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US7067722B2 (en) 1999-08-26 2006-06-27 Monsanto Technology Llc Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
BR0013607A (pt) 1999-08-26 2002-04-30 Calgene Llc Sequências de ácidos nucléicos e processos de uso para a produção de plantas com ácidos graxos poliinsaturados modificados
US7531718B2 (en) 1999-08-26 2009-05-12 Monsanto Technology, L.L.C. Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
GB9927444D0 (en) * 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
DE10160151A1 (de) * 2001-01-09 2003-06-26 Ribopharma Ag Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
DE10100586C1 (de) * 2001-01-09 2002-04-11 Ribopharma Ag Verfahren zur Hemmung der Expression eines Ziegens
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
CA2404890C (fr) 2000-03-30 2013-11-19 Whitehead Institute For Biomedical Research Mediateurs d'interference arn specifiques de sequences arn
BRPI0115814B8 (pt) 2000-12-01 2021-05-25 Europaeisches Laboratorium Fuer Molekularbiologie Embl moléculas de rna de filamento duplo, seu método de preparação e composição farmacêutica compreendendo as mesmas
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
EP1229134A3 (fr) 2001-01-31 2004-01-28 Nucleonics, Inc Utilisation de l'inhibition post-transcriptionnelle pour l'identification des séquences d'acides nucléiques qui modifient la fonction d'une cellule
US7612194B2 (en) 2001-07-24 2009-11-03 Monsanto Technology Llc Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof
US7745418B2 (en) 2001-10-12 2010-06-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
WO2003035083A1 (fr) * 2001-10-26 2003-05-01 Ribopharma Ag Medicament destine a traiter une fibrose par interference d'arn
BR0308424A (pt) 2002-03-14 2005-02-22 Commw Scient Ind Res Org Métodos e meios para infra-regular eficientemente a expressão de qualquer gene de interesse em células e organismos eucarióticos
US7166771B2 (en) 2002-06-21 2007-01-23 Monsanto Technology Llc Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
US7566813B2 (en) 2002-03-21 2009-07-28 Monsanto Technology, L.L.C. Nucleic acid constructs and methods for producing altered seed oil compositions
EP1484959A4 (fr) 2002-03-21 2005-08-31 Monsanto Technology Llc Constructions d'acides nucleiques et procedes de production de compositions d'huile de graines modifiees
US20040180438A1 (en) 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
SI3222724T1 (sl) 2002-08-05 2019-03-29 Silence Therapeutics Gmbh Nadaljnje nove oblike molekul interferenčne RNA
US7078234B2 (en) 2002-12-18 2006-07-18 Monsanto Technology Llc Maize embryo-specific promoter compositions and methods for use thereof
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
SI1575977T1 (sl) * 2002-12-23 2010-01-29 Dynavax Tech Corp Imunostimulirni sekvenčni polinukleotidi in postopki za njihovo uporabo
CN1836045B (zh) 2003-03-28 2012-05-09 孟山都技术有限公司 用于早期种子发育的新型植物启动子
US20060041961A1 (en) 2004-03-25 2006-02-23 Abad Mark S Genes and uses for pant improvement
US20060021087A1 (en) 2004-04-09 2006-01-26 Baum James A Compositions and methods for control of insect infestations in plants
US20060075522A1 (en) 2004-07-31 2006-04-06 Jaclyn Cleveland Genes and uses for plant improvement
EP2489726A3 (fr) 2005-01-12 2012-11-28 Monsanto Technology LLC Gènes et utilisation pour l'amélioration de plantes
ATE552343T1 (de) 2005-04-19 2012-04-15 Basf Plant Science Gmbh Endosperm-spezifische expression und/oder expression in keimenden embryos monokotyledoner pflanzen
PL2431473T3 (pl) 2005-09-16 2017-05-31 Monsanto Technology Llc Sposoby genetycznej kontroli inwazji owadów u roślin i kompozycje do tego przeznaczone
CA2622671C (fr) 2005-09-16 2020-12-22 Devgen Nv Procede de protection phytosanitaire a base d'interference arn
CA2622660C (fr) 2005-09-16 2017-11-07 Devgen Nv Procedes bases sur des plantes transgeniques pour organismes nuisibles de plantes mettant en oeuvre l'arn interference (arni)
BRPI0707626A2 (pt) 2006-02-10 2011-05-10 Monsanto Technology Llc identificaÇço e uso de genes alvos para o controle de nematàides parasitas de plantas
CA2836368C (fr) 2006-02-13 2020-04-07 Monsanto Technology Llc Selection et stabilisation de constructions d'arn double brin
CN101421406B (zh) 2006-02-13 2016-08-31 孟山都技术有限公司 用于产生改变的种子油组成的核酸构建体和方法
CN101195821A (zh) 2006-12-04 2008-06-11 中国科学院上海生命科学研究院 利用RNAi技术改良植物抗虫性的方法
CA2675926A1 (fr) 2007-02-16 2008-08-21 Basf Plant Science Gmbh Sequences d'acides nucleiques pour la regulation de l'expression specifique de l'embryon dans des plantes monocotyles
US8329989B2 (en) 2008-09-29 2012-12-11 Monsanto Technology Llc Soybean transgenic event MON87705 and methods for detection thereof
MX2011011076A (es) 2009-04-20 2011-11-18 Monsanto Technology Llc Resistencia a multiples virus en plantas.
EP3354735A1 (fr) 2010-12-30 2018-08-01 Dow AgroSciences LLC Molécules d'acide nucléique ciblant la petite protéine de liaison gtp rho1 et conférant une résistance aux coléoptères nuisibles
UY33851A (es) 2010-12-30 2012-07-31 Dow Agrosciences Llc Moléculas de ácido nucleico que confieren resistencia a las plagas de coleópteros
BRPI1107329A2 (pt) 2010-12-30 2019-11-19 Dow Agrosciences Llc moléculas de ácido nucléico que direcionadas à subunidade h de atpase vacuolar que conferem resistência a pragas de coleópteros, vetor de transformação de planta, célula transformada, bem como métodos para controlar uma população de praga de coleóptero, controlar uma infestação pela dita praga, melhorar o rendimento de uma safra e para produzir uma célula transgênica
BRPI1107332A2 (pt) 2010-12-30 2018-10-30 Dow Agrosciences Llc polinucleotídeo, vetor de transformação, moléculas de ácido nucleico, célula, bem como métodos para controle de praga coleóptera, para aperfeiçoamento do rendimento de cultura de milho, e para produção de célula e planta resistentes à praga coleóptera
US9688983B2 (en) 2012-12-20 2017-06-27 Dow Agrosciences Llc Nucleic acid molecules that confer resistance to coleopteran pests
EP2810952A1 (fr) 2013-06-03 2014-12-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Nouveaux procédés de lutte contre les nuisibles
MX2016008263A (es) 2013-12-20 2017-05-09 Dow Agrosciences Llc Moleculas de acido nucleico rnapii 140 que confieren resistencia a plagas de coleopteros.
BR102014031844A2 (pt) 2013-12-20 2015-10-06 Dow Agrosciences Llc ras oposto (rop) e moléculas de ácido nucleico relacionadas que conferem resistência a pragas de coleópteros e hemípteros
MX366975B (es) 2014-03-12 2019-08-01 Univ Sydney Produccion de arn en plantas superiores.
AU2015255995B2 (en) 2014-05-07 2018-05-10 Dow Agrosciences Llc Dre4 nucleic acid molecules that confer resistance to coleopteran pests
US20160194658A1 (en) 2014-12-22 2016-07-07 Dow Agrosciences Llc Nucampholin nucleic acid molecules to control coleopteran insect pests
EP3067424A1 (fr) 2015-03-13 2016-09-14 Dow AgroSciences LLC Molécules d'acide nucléique d'arn polymérase i1 permettant de lutter contre les insectes nuisibles
US20180105832A1 (en) 2015-04-13 2018-04-19 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Novel aflatoxin and fungal infection control methods
BR102016012010A2 (pt) 2015-05-29 2020-03-24 Dow Agrosciences Llc Molécula de ácido nucleico, de ácido ribonucleico (rna) e de ácido ribonucleico de filamento duplo (dsrna), usos de célula, planta e semente, produto primário, bem como métodos para controlar uma população de pragas coleópteras e/ou hemípteras, para melhorar o rendimento de uma cultura, e para produzir uma célula vegetal transgênica e uma planta transgênica
CN108431207A (zh) 2015-10-12 2018-08-21 美国陶氏益农公司 赋予对鞘翅目和半翅目害虫的抗性的wupa核酸分子
AU2016371636A1 (en) 2015-12-18 2018-06-21 Dow Agrosciences Llc Ribosomal protein L40 (RPL40) nucleic acid molecules that confer resistance to coleopteran and hemipteran pests
WO2018089237A1 (fr) 2016-11-10 2018-05-17 Dow Agrosciences Llc Molécules d'acide nucléique de cytochrome b (cytb) qui régulent des pathogènes
EP3342780A1 (fr) 2016-12-30 2018-07-04 Dow AgroSciences LLC Molécules d'acides nucléiques prp8 (prétraitement de l'arnm du facteur 8) pour lutter contre les insectes nuisibles
EP3825408A1 (fr) 2019-11-19 2021-05-26 FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. Procédés de lutte contre les insectes nuisibles multi-espèces

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2675803B1 (fr) * 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
JP3110460B2 (ja) * 1992-04-17 2000-11-20 麒麟麦酒株式会社 複数のウィルスに抵抗性を持つ植物及びその作製法
NZ255028A (en) * 1992-07-02 1997-03-24 Hybridon Inc Antisense oligonucleotides resistant to nucleolytic degradation
GB2273932A (en) * 1992-11-24 1994-07-06 Stiefel Laboratories Stable oligonucleotides
FR2703053B1 (fr) * 1993-03-26 1995-06-16 Genset Sa Oligonucleotides agrafes et semi-agrafes, procede de preparation et applications .
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9805770A3 *

Also Published As

Publication number Publication date
WO1998005770A2 (fr) 1998-02-12
WO1998005770A3 (fr) 1998-03-26
DE19631919C2 (de) 1998-07-16
DE19631919A1 (de) 1998-02-12

Similar Documents

Publication Publication Date Title
DE19631919C2 (de) Anti-Sinn-RNA mit Sekundärstruktur
EP1798285B1 (fr) Méthode et médicament destinés à inhiber l'expression d'une gène donnée
DE69232032T3 (de) Antisense oligonukleotide
EP0519463B1 (fr) Oligonucléotides catalytiques, synthétiques
DE3852539T3 (de) Ribozyme.
DE19935756A1 (de) Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
EP0753580A2 (fr) Thérapie génique à spécificité cellulaire, utilisant le promoteur de l'inhibiteur de métalloprotéinases d'origine tissulaire du type 3
DE69634698T2 (de) Gewebespezifische und ziel-rna-spezifische ribozyme
DE69233106T2 (de) Verfahren zur Herstellung von Einzelsträndigen "stem-loop" DNS
EP1951870B1 (fr) Produits de recombinaison de l'adn pour l'inhibition specifique de l'expression de genes par interference arn
DE69937444T2 (de) Isolierte und aufgereinigte nukleinsäuren, welche ein gen enthalten, welches in hopfendrüsen exprimiert wird
EP0299303B1 (fr) Vecteurs d'expression eucaryotiques avec des sous-unités "enhancer" multimériques, procédé pour la préparation et utilisation
DE3819463A1 (de) Expressionsvektoren zur herstellung unfusionierter proteine in mikroorganismen
DE4444949C1 (de) Vektoren und Viren zur Gentherapie
WO1998005771A1 (fr) Procede pour accroitre l'effet d'arn antisens dans des cellules
DE69933382T2 (de) Herstellung von ssdna innerhalb der zelle
DE4422259C2 (de) Anti-Sinn-Oligonukleotide zur Aromatase-Inhibierung
WO2000043501A2 (fr) Ribozymes diriges contre la sous-unite catalytique de la telomerase humaine (htert)
WO2001005993A1 (fr) Absorption cellulaire d'adn
DE3929822A1 (de) Vektor und seine verwendung
WO2002074953A2 (fr) Bibliotheque genetique et procede de fabrication
EP0733713A1 (fr) Procédé de mesure les activités régulatrices de la transcription de séquences de DNA

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990128

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 20020313

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030301